NasdaqGS:BIIBBiotechs
Biogen (BIIB) Q4 Loss And Margin Compression Reinforce Bearish Profitability Narratives
Biogen FY 2025 earnings snapshot
Biogen (BIIB) has wrapped up FY 2025 with Q4 revenue of US$2,279.4 million and a basic EPS loss of US$0.33, as the market weighs these numbers against already softening profitability. Over the past six quarters, revenue has moved from US$2,465.8 million in Q3 2024 to a peak of US$2,645.5 million in Q2 2025 before landing at US$2,279.4 million in Q4 2025. Quarterly EPS has ranged from US$2.67 in Q3 2024 up to US$4.33 in Q2 2025 before turning negative in the...